Reported Earnings • Jul 29
Second quarter 2026 earnings released: EPS: US$0.031 (vs US$0.037 in 2Q 2025) Second quarter 2026 results: EPS: US$0.031 (down from US$0.037 in 2Q 2025). Revenue: US$266.8m (up 20% from 2Q 2025). Net income: US$7.70m (down 7.2% from 2Q 2025). Profit margin: 2.9% (down from 3.7% in 2Q 2025). Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Electronic industry in Germany. Over the last 3 years on average, earnings per share has increased by 121% per year but the company’s share price has only increased by 30% per year, which means it is significantly lagging earnings growth. Announcement • Jul 29
Mirion Technologies, Inc. Reaffirms Earnings Guidance for the Fiscal Year Ending December 31, 2026 Mirion Technologies, Inc. reaffirmed earnings guidance for the fiscal year ending December 31, 2026. For the year, the company's revenue growth of approximately 22.0% – 24.0%; includes foreign exchange rate and acquisition-related tailwinds. New Risk • Jul 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.5x net interest cover). Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (17% increase in shares outstanding). Announcement • Jul 16
Mirion Technologies, Inc. to Report Q2, 2026 Results on Jul 28, 2026 Mirion Technologies, Inc. announced that they will report Q2, 2026 results After-Market on Jul 28, 2026 Board Change • May 20
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 1 highly experienced director. Independent Director Sheila Rege was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Apr 29
Mirion Technologies, Inc. Reaffirms Earnings Guidance for the Fiscal Year Ending December 31, 2026 Mirion Technologies, Inc. reaffirmed earnings guidance for the fiscal year ending December 31, 2026. For the year, the company expects Revenue growth of approximately 22.0% – 24.0%; includes foreign exchange rate and acquisition-related tailwinds. Announcement • Apr 16
Mirion Technologies, Inc. to Report Q1, 2026 Results on Apr 28, 2026 Mirion Technologies, Inc. announced that they will report Q1, 2026 results After-Market on Apr 28, 2026 Announcement • Apr 02
Mirion Technologies, Inc., Annual General Meeting, May 13, 2026 Mirion Technologies, Inc., Annual General Meeting, May 13, 2026. Announcement • Jan 22
Mirion Technologies, Inc. to Report Q4, 2025 Results on Feb 10, 2026 Mirion Technologies, Inc. announced that they will report Q4, 2025 results After-Market on Feb 10, 2026 Announcement • Dec 02
Mirion Technologies, Inc. (NYSE:MIR) completed the acquisition of Paragon Energy Solutions, LLC from Windjammer Capital Investors LLC. Mirion Technologies, Inc. (NYSE:MIR) entered into a definitive agreement to acquire Paragon Energy Solutions, LLC from Windjammer Capital Investors LLC for approximately $590 million on September 24, 2025. The transaction is subject to working capital and other customary purchase price adjustments. The financing of the Acquisition, Mirion has obtained $585 million in incremental term loan commitments from Goldman Sachs Lending Partners LLC, pursuant to a debt commitment letter and is supported by a fully committed bridge facility. The transaction will also be financed through a $350 million public offering and $250 Million convertible notes due 2031.The transaction is valued at an approximate multiple of 18 times the estimated 2026 Adjusted EBITDA.
The closing of the Acquisition is subject to customary closing conditions, including: (i) expiration or termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, and receipt of approval from the U.S. Nuclear Regulatory Commission related to the transfer of a nuclear export license, (ii) the absence of any law, injunction or other governmental order that prohibits the consummation of the Acquisition; and (iii) other customary closing conditions, including the accuracy of the parties’ representations and warranties (subject to certain materiality qualifications) and each party’s compliance with its covenants and agreements contained in the Equity Purchase Agreement.
The transaction is expected to close before year end 2025. The acquisition is anticipated to be accretive to diluted EPS in the first full year post close.
Goldman Sachs & Co. LLC acted as financial advisor for Mirion Technologies, Inc. Alan F. Denenberg, Michael Diz, Hilary Dengel, Frank Azzopardi, Patrick E. Sigmon and Adam Kaminsky of Davis Polk & Wardwell LLP acted as legal advisor for Mirion Technologies, Inc. Robert W. Baird & Co. Incorporated acted as financial advisor for Paragon Energy Solutions, LLC. Moelis & Company acted as financial advisor for Paragon Energy Solutions, LLC. Annie Cataldo, Amanda C. Border, Christian A. Atwood and Vincent P. Thorn of Kirkland & Ellis LLP acted as legal advisor for Paragon Energy Solutions, LLC.
Mirion Technologies, Inc. (NYSE:MIR) completed the acquisition of Paragon Energy Solutions, LLC from Windjammer Capital Investors LLC on December 1, 2025. Announcement • Oct 29
Mirion Technologies, Inc. Reaffirms Earnings Guidance for the Full Year Ending December 31, 2025 Mirion Technologies, Inc. reaffirmed earnings guidance for the full year ending December 31, 2025. For the year, the company reaffirmed revenue growth of approximately 7.0% – 9.0%; includes a foreign exchange rate tailwind of approximately 180 basis points using a fourth quarter Euro-to-USD exchange rate of 1.16 and acquisitions-related benefit (Certrec and Oncospace) of approximately 100 basis points. Organic Revenue growth of approximately 4.5% – 6.0%. Announcement • Oct 16
Mirion Technologies, Inc. to Report Q3, 2025 Results on Oct 28, 2025 Mirion Technologies, Inc. announced that they will report Q3, 2025 results at 4:00 PM, US Eastern Standard Time on Oct 28, 2025 Announcement • Sep 26
Mirion Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $369.565212 million. Mirion Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $369.565212 million.
Security Name: Class A Common Stock
Security Type: Common Stock
Securities Offered: 17,309,846
Price\Range: $21.35 Announcement • Sep 25
Mirion Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $349.999993 million. Mirion Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $349.999993 million.
Security Name: Class A Common Stock
Security Type: Common Stock
Securities Offered: 14,227,642
Price\Range: $24.6 Announcement • Sep 24
Mirion Technologies, Inc. (NYSE:MIR) entered into a definitive agreement to acquire Paragon Energy Solutions, LLC from Windjammer Capital Investors LLC for approximately $590 million. Mirion Technologies, Inc. (NYSE:MIR) entered into a definitive agreement to acquire Paragon Energy Solutions, LLC from Windjammer Capital Investors LLC for approximately $590 million on September 24, 2025. The transaction is subject to working capital and other customary purchase price adjustments. The financing of the Acquisition, Mirion has obtained $585 million in incremental term loan commitments from Goldman Sachs Lending Partners LLC, pursuant to a debt commitment letter and is supported by a fully committed bridge facility.
The closing of the Acquisition is subject to customary closing conditions, including: (i) expiration or termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, and receipt of approval from the U.S. Nuclear Regulatory Commission related to the transfer of a nuclear export license, (ii) the absence of any law, injunction or other governmental order that prohibits the consummation of the Acquisition; and (iii) other customary closing conditions, including the accuracy of the parties’ representations and warranties (subject to certain materiality qualifications) and each party’s compliance with its covenants and agreements contained in the Equity Purchase Agreement.
The transaction is expected to close before year end 2025. The acquisition is anticipated to be accretive to diluted EPS in the first full year post close.
Goldman Sachs & Co. LLC acted as financial advisor for Mirion Technologies, Inc. Alan F. Denenberg, Michael Diz, Hilary Dengel, Frank Azzopardi, Patrick E. Sigmon and Adam Kaminsky of Davis Polk & Wardwell LLP acted as legal advisor for Mirion Technologies, Inc. Robert W. Baird & Co. Incorporated acted as financial advisor for Paragon Energy Solutions, LLC. Moelis & Company acted as financial advisor for Paragon Energy Solutions, LLC. Annie Cataldo, Amanda C. Border, Christian A. Atwood and Vincent P. Thorn of Kirkland & Ellis LLP acted as legal advisor for Paragon Energy Solutions, LLC. Announcement • Jul 22
Mirion Technologies Unveils the Vital Platform, a Digital Ecosystem Powering Integrated Operations for Nuclear Energy and Beyond Mirion Technologies announced the launch of the Vital Platform. This software offers a single, unified system for accessing data across nuclear power sites to work more efficiently, enhance worker safety, and solve operational challenges faster. The launch includes the platform's first application, Vital Supervision, designed to enhance radiological instrument data visibility, improve response times, and simplify oversight across critical radiological systems. The Vital Platform was developed to meet nuclear industry demands for a more connected and efficient way to manage radiological instrument data. Rather than relying on fragmented systems or manual processes, Vital enables teams to work within one streamlined environment prioritizing speed, security, and long-term adaptability. Key benefits to customers include: Data Integration and Real Time Monitoring: Real-time tracking across systems enables faster, proactive responses. Regulatory Compliance and Reporting: Automated, standardized reporting simplifies regulatory alignment. Operational Efficiency and Cost Reduction: Streamlined workflows cut time, reduce errors, and lower costs. Security and Risk Mitigation: Access controls and cybersecurity safeguard sensitive data. Facilitating Advanced Analytics: Detailed data helps predict risks and improve decision-making. Scalability and Future Proofing: Modular design supports growth and adapts to change. Supervision: The First Vital Platform Application. Vital Supervision is the first in a series of applications to be built on the Vital Platform, with the aim to unify the capabilities of siloed, standalone software into one platform. This application simplifies the collection and analysis of data from a wide variety of radiological instruments. Real-time, at-a-glance access to alarms, measurement data and instrument health significantly enhances the monitoring and management of critical equipment. The Vital Platform and Vital Supervision application will be showcased at two key upcoming industry events. A webbinar presentation facilitated through Nuclear Engineering International (July 23) and Mirion's annual users' conference Mirion Connect (July 28-August 1) will offer opportunities to explore platform capabilities in depth. Announcement • Jul 17
Mirion Technologies, Inc. to Report Q2, 2025 Results on Jul 31, 2025 Mirion Technologies, Inc. announced that they will report Q2, 2025 results After-Market on Jul 31, 2025 Announcement • Jun 20
Mirion Medical to Debut New Solutions, Highlight Broad Radiopharma-Focused Portfolio At Snmmi Annual Meeting Mirion announced that its Mirion Medical group will showcase its portfolio of solutions designed to enable the radiopharma and theranostic fields at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, June 21-24, in New Orleans, Louisiana. New products from Capintec and Dosimetry Services will be introduced alongside innovations from the broader Mirion portfolio, including the ec2 Software suite and advances from Mirion Technologies. Deuting at the 2025 SNMMI Annual Meeting: Graves Phantom from Capintec, a Mirion Medical company: The Graves Phantom is a solution for enabling precise dosimetry in radiopharmaceutical therapy (RPT). Designed as a 20-cm tissue-equivalent Phantom, it supports the calibration of SPECT systems per radioisotope and allows for accurate sensitivity factor measurements under realistic scatter conditions, enabling reliable and reproducible RPT workflows. Instadose®?VUE Beta Dosimeter from Dosimetry Services, a Mirion Medical company; The only hybrid wireless dosimeter designed for theranostic applications, the InstadoseVUE Beta device tracks and measures radiation exposure, ensuring the safety of medical staff in environments where beta radiation is present. The InstadoseVUE Beta is the latest model in the InstadoseVUE line of wireless dosimeters for radiation monitoring of personnel. Additional Featured Solutions from the Broader Mirion Portfolio: ec2 Software Suite: ec2 Software, a Mirion Medical company, provides software to simplify workflows, support regulatory compliance, and drive operational efficiency for stakeholders across the nuclear medicine, molecular imaging and radiopharmaceutical fields. Demonstrations for applications including BioTrax™? QMS, NMIS™?, and BioRx™? will be available throughout the SNMMI Annual Meeting. Apex-Guard™? Software: From Mirion Technologies, the newest version of Apex-Guard software includes a robust impurity analysis feature and patent-pending algorithm for gamma spectroscopy measurements, which simplifies radioisotope production quality management, boosts confidence in radioisotope safety, and aids in regulatory compliance. The software integrates with BioTrax QMS, improving workflow efficiency and data integrity. Portable and Mobile Radiation Monitoring: New solutions from Mirion Technologies include the CSPevo®? Probe and RDS-Med™? Survey Meter for comprehensive, portable radiation survey monitoring and the IC3™? Portable Ion Chamber Survey Meter for measuring gamma, beta and X-ray radiation. In addition, the iCAM™? Mobile Alpha/Beta Particulate Monitor for reliable monitoring of airborne activity will be on hand. Commitment to Patient Care and Safety: Mirion Medical is a proud sponsor of the SNMMI 2025 Patient Education Day, contributing educational resources and insights on radiation safety. This sponsorship reflects Mirion's commitment to patient education and awareness, ensuring that patients and their families are well-informed about the benefits of nuclear medicine and molecular imaging. Announcement • Apr 30
Mirion Technologies, Inc. Revises Earnings Guidance for the Full Year 2025 Mirion Technologies, Inc. revised earnings guidance for the full year 2025. Revenue growth of approximately 5.0% – 7.0% (previously 4.0% – 6.0%); includes a foreign exchange rate headwind of approximately 40 basis points using a Euro-to-USD exchange rate of 1.08. Organic Revenue growth of approximately 5.5% – 7.5% (no change from previous guidance); includes an approximately 30 basis point lasers business closure headwind from 2024. Announcement • Apr 21
Mirion Technologies, Inc. to Report Q1, 2025 Results on Apr 29, 2025 Mirion Technologies, Inc. announced that they will report Q1, 2025 results After-Market on Apr 29, 2025 Announcement • Apr 03
Mirion Technologies, Inc., Annual General Meeting, May 15, 2025 Mirion Technologies, Inc., Annual General Meeting, May 15, 2025. Announcement • Apr 02
Mirion Technologies, Inc. to Elevate Radiopharmaceutical Production Quality with Advanced Apex-Guard Software Mirion Technologies announced the latest release of its Apex-Guard gamma spectroscopy software. Tailored to meet the stringent regulatory demands of commercial radioisotope producers, Apex-Guard software V1.2 significantly enhances the Mirion solutions suite within the radiopharmaceutical supply chain with a robust impurity analysis for radioisotope producers. This software release reinforces the Mirion commitment to improving quality in cancer care, through focused innovation across its Mirion Technologies and Mirion Medical groups. The radiopharmaceutical field is experiencing rapid expansion, with over 100 drugs currently in Phase I or further clinical development stages poised to revolutionize patient-centric diagnosis and treatment in cancer care and other medical specialties. To manage the growth, radioisotope producers require robust quality management and impurity analysis to ensure compliance and patient safety. Building on the established Mirion Technologies Genie and Apex-Gamma gamma spectroscopy software platforms, Apex-Guard software offers advanced controls, security, audit features, and data integrity. These features support compliance with regulations such as U.S. FDA 21 CFR Part 112. The latest version introduces a solution for Radionuclidic purity gamma spectroscopy measurements through a broadly applicable, ready-to-use patent-pending algorithm. This advancement streamlines quality management processes, increases confidence in quality and facilitates efficient regulatory compliance. Apex-Guard software further enhances the radiopharmaceutical lifecycle through streamlined workflows via interoperability with industry-leader BioTrax QMS, an electronic quality management tool encompassing inventory management, document management, and production batch records from ec2 Software, a Mirion Medical Company. Announcement • Mar 01
Mirion Technologies Site in Munich Achieves ISO 19443 Certification Mirion Technologies announced that its site in Munich, Germany, has been awarded with the International Organization for Standardization (ISO) certification ISO 19343:2018, a nuclear-specific quality management standard dedicated to organizations supplying products and services important to nuclear safety (ITNS). Such achievement emphasizes the company's commitment to maintaining stringent quality and safety standards specific to the nuclear sector. The Mirion Technologies site in Munich, a full-service provider for Radiation and Neutron Flux Monitoring Systems, is one of a few companies in Germany to receive this certification, building on its long-standing ISO 9001 certification and further enhancing the Mirion commitment to excellence. The audit was conducted by TUV Sud France, accredited by the French Accreditation Body COFRAC. The certification audit specifically highlighted the company's clear line of responsibility, quality concept and emphasis on nuclear quality goals. The auditors also praised the interaction between departments and the well-structured approach to projects and developments. The Munich site joins three other Mirion locations to achieve the ISO 19343 certification. Mirion Technologies sites in France (Lamanon and Fussy) are also accredited. Announcement • Feb 13
Mirion Technologies, Inc. Reaffirms Earnings Guidance for the Year Ending December 31, 2025 Mirion Technologies, Inc. reaffirmed earnings guidance for the year ending December 31, 2025. For the year, the company reaffirmed revenue growth of approximately 4.0% – 6.0%; includes a foreign exchange rate headwind of approximately 190 basis points. Organic Revenue growth of approximately 5.5% – 7.5%; includes an approximately 30 basis point lasers business closure headwind from 2024. Announcement • Jan 17
Mirion Technologies, Inc. to Report Q4, 2024 Results on Feb 11, 2025 Mirion Technologies, Inc. announced that they will report Q4, 2024 results After-Market on Feb 11, 2025 Announcement • Dec 04
Mirion Technologies, Inc. Provides Earnings Guidance for the Year 2025 Mirion Technologies, Inc. provided earnings guidance for the year 2025. For the year, the company expects Organic revenue growth of approximately 5.5% - 7.5%; includes an approximately 30 basis point lasers business divestiture headwind from 2024. Revenue growth of approximately 4.0% - 6.0%; includes a foreign exchange rate headwind of approximately 150 basis points. Announcement • Dec 03
Mirion Technologies, Inc. (NYSE:MIR) announces an Equity Buyback for $100 million worth of its shares. Mirion Technologies, Inc. announces a share repurchase program. Under the program, the company will repurchase up to $100 million worth of its Class A common stock. Reported Earnings • Oct 30
Third quarter 2024 earnings released: US$0.066 loss per share (vs US$0.061 loss in 3Q 2023) Third quarter 2024 results: US$0.066 loss per share (further deteriorated from US$0.061 loss in 3Q 2023). Revenue: US$206.8m (up 8.2% from 3Q 2023). Net loss: US$13.6m (loss widened 12% from 3Q 2023). Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Electronic industry in Germany. Over the last 3 years on average, earnings per share has increased by 143% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Announcement • Oct 30
Mirion Technologies, Inc. Revises Financial Guidance for the Fiscal Year Ending December 31, 2024 Mirion Technologies, Inc. revised financial guidance for the fiscal year ending December 31, 2024. For the period, the company expects revenue growth of 6% to 7%, compared to 5% to 7% previously and Organic revenue growth of 5% to 6%, compared to 4% to 6% previously. New Risk • Oct 21
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$31m net loss next year). Share price has been volatile over the past 3 months (7.9% average weekly change). Shareholders have been diluted in the past year (3.1% increase in shares outstanding). Significant insider selling over the past 3 months (€250k sold). Announcement • Oct 17
Mirion Technologies, Inc. to Report Q3, 2024 Results on Oct 29, 2024 Mirion Technologies, Inc. announced that they will report Q3, 2024 results After-Market on Oct 29, 2024 New Risk • Aug 09
New minor risk - Insider selling There has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: €328k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$27m net loss next year). Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (3.1% increase in shares outstanding). Significant insider selling over the past 3 months (€328k sold). Announcement • Aug 03
Mirion Technologies, Inc. Reiterates Revenue Guidance for the Full Year Period Ending December 31, 2024 Mirion Technologies, Inc. reiterated revenue guidance for the full year period ending December 31, 2024. For the year, the company expects revenue growth guidance of 5% to 7%. Organic revenue growth of 4% - 6%, which is unchanged. Reported Earnings • Aug 02
Second quarter 2024 earnings released: US$0.058 loss per share (vs US$0.14 loss in 2Q 2023) Second quarter 2024 results: US$0.058 loss per share (improved from US$0.14 loss in 2Q 2023). Revenue: US$207.1m (up 5.0% from 2Q 2023). Net loss: US$11.7m (loss narrowed 58% from 2Q 2023). Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Electronic industry in Germany. New Risk • Aug 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$32m net loss next year). Share price has been volatile over the past 3 months (6.6% average weekly change). Shareholders have been diluted in the past year (3.6% increase in shares outstanding). Announcement • Jul 20
Mirion Technologies, Inc. to Report Q2, 2024 Results on Aug 01, 2024 Mirion Technologies, Inc. announced that they will report Q2, 2024 results After-Market on Aug 01, 2024 New Risk • Jul 20
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$32m net loss next year). Shareholders have been diluted in the past year (3.6% increase in shares outstanding). New Risk • Jun 11
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$32m net loss next year). Shareholders have been diluted in the past year (3.6% increase in shares outstanding). New Risk • May 25
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$32m net loss next year). Shareholders have been diluted in the past year (2.7% increase in shares outstanding). Breakeven Date Change • May 02
No longer forecast to breakeven The 3 analysts covering Mirion Technologies no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$91.3m in 2025. New consensus forecast suggests the company will make a loss of US$12.8m in 2025. Reported Earnings • May 01
First quarter 2024 earnings released: US$0.13 loss per share (vs US$0.22 loss in 1Q 2023) First quarter 2024 results: US$0.13 loss per share (improved from US$0.22 loss in 1Q 2023). Revenue: US$192.6m (up 5.8% from 1Q 2023). Net loss: US$25.8m (loss narrowed 38% from 1Q 2023). Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Electronic industry in Germany. Announcement • May 01
Mirion Technologies, Inc. Reaffirms Earnings Guidance for the Year Ending December 31, 2024 Mirion Technologies, Inc. reaffirmed earnings Guidance for the year ending December 31, 2024. The company expected revenue growth of 5% - 7%. Organic revenue growth of 4% - 6%. Board Change • Apr 25
High number of new directors There are 6 new directors who have joined the board in the last 3 years. Independent Director Sheila Rege was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Announcement • Apr 24
Mirion Technologies, Inc., Annual General Meeting, Jun 04, 2024 Mirion Technologies, Inc., Annual General Meeting, Jun 04, 2024, at 10:00 US Eastern Standard Time. Agenda: To consider Elect directors for a one-year term; to Ratify the appointment of Deloitte & Touche, LLP (“Deloitte”) as company's independent registered public accounting firm for the fiscal year ending December 31, 2024; to Approve, on a non-binding advisory basis, the compensation of company's named executive officers as disclosed in the accompanying proxy statement (the “Say-on-Pay Proposal”); and to transact any other business as may properly come before the meeting or any adjournment, postponement or continuation thereof. New Risk • Apr 24
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 9.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$13m net loss in 2 years). Shareholders have been diluted in the past year (9.5% increase in shares outstanding). Announcement • Apr 19
Mirion Technologies, Inc. to Report Q1, 2024 Results on Apr 30, 2024 Mirion Technologies, Inc. announced that they will report Q1, 2024 results After-Market on Apr 30, 2024 Reported Earnings • Mar 04
Full year 2023 earnings released: US$0.49 loss per share (vs US$1.53 loss in FY 2022) Full year 2023 results: US$0.49 loss per share (improved from US$1.53 loss in FY 2022). Revenue: US$800.9m (up 12% from FY 2022). Net loss: US$96.9m (loss narrowed 65% from FY 2022). Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Electronic industry in Germany. Breakeven Date Change • Feb 15
No longer forecast to breakeven The 3 analysts covering Mirion Technologies no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$91.3m in 2025. New consensus forecast suggests the company will make a loss of US$12.5m in 2025. Reported Earnings • Feb 14
Full year 2023 earnings released: US$0.49 loss per share (vs US$1.53 loss in FY 2022) Full year 2023 results: US$0.49 loss per share (improved from US$1.53 loss in FY 2022). Revenue: US$800.9m (up 12% from FY 2022). Net loss: US$96.9m (loss narrowed 65% from FY 2022). Revenue is forecast to grow 4.6% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Electronic industry in Germany. Announcement • Feb 14
Mirion Technologies, Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2024 Mirion Technologies, Inc. provided earnings guidance for the fiscal year ending December 31, 2024. For the year, the company expects revenue growth of 5% - 7%, and Organic revenue growth of 4% - 6%. Announcement • Feb 01
Mirion Technologies, Inc. to Report Q4, 2023 Results on Feb 13, 2024 Mirion Technologies, Inc. announced that they will report Q4, 2023 results After-Market on Feb 13, 2024 Announcement • Nov 03
Mirion Technologies, Inc. (NYSE:MIR) acquired Nuclear Medicine Information Systems, LLC for $33 million. Mirion Technologies, Inc. (NYSE:MIR) acquired Nuclear Medicine Information Systems, LLC for $33 million on November 1, 2023. The ec 2 team and portfolio of solutions will be integrated into Mirion’s Nuclear Medicine business unit.Mirion Technologies, Inc. (NYSE:MIR) completed the acquisition of Nuclear Medicine Information Systems, LLC on November 1, 2023. Reported Earnings • Nov 02
Third quarter 2023 earnings released: US$0.061 loss per share (vs US$0.26 loss in 3Q 2022) Third quarter 2023 results: US$0.061 loss per share (improved from US$0.26 loss in 3Q 2022). Revenue: US$191.2m (up 19% from 3Q 2022). Net loss: US$12.1m (loss narrowed 74% from 3Q 2022). Revenue is forecast to grow 3.9% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Electronic industry in Germany. Announcement • Nov 02
Mirion Technologies, Inc. Reiterates Revenue Guidance for the Twelve Month Period Ending December 31, 2023 Mirion Technologies, Inc. reiterates revenue guidance for the twelve month period ending December 31, 2023. The company expects Revenue growth of 8% - 10% and Organic revenue growth of 6% - 8%. Announcement • Oct 19
Mirion Announces Resignation of Michael Rossi as Medical Group President, Effective November 1, 2023 Mirion announced that Michael Rossi has informed the Company of his decision to resign as Medical Group President, effective November 1, 2023, in order to assume a CEO role at another public company. Mirion’s Chief Executive Officer, Thomas Logan, will reassume the responsibilities of Medical Group President until a permanent successor is named. Mr. Logan had previously served as acting Medical Group President through much of 2022. Announcement • Oct 18
Mirion Technologies, Inc. to Report Q3, 2023 Results on Nov 01, 2023 Mirion Technologies, Inc. announced that they will report Q3, 2023 results After-Market on Nov 01, 2023 New Risk • Aug 04
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: US$270m Forecast net loss in 1 year: US$59m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$59m net loss next year). Shareholders have been diluted in the past year (9.3% increase in shares outstanding). Breakeven Date Change • Aug 03
No longer forecast to breakeven The 3 analysts covering Mirion Technologies no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$60.9m in 2023. New consensus forecast suggests the company will make a loss of US$32.3m in 2024. Announcement • Aug 03
Mirion Technologies, Inc. Updates Its Revenue Guidance for the Fiscal Year Ending December 31, 2023 Mirion Technologies, Inc. updated its revenue guidance for the fiscal year ending December 31, 2023. For the period, the company expects revenue growth of8% - 10%, compared to 6% - 9% previously and Organic revenue growth of 6% - 8%, compared to 4% - 7% previously. New Risk • Jul 31
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 9.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company. Announcement • Jul 23
Mirion Technologies, Inc. to Report Q2, 2023 Results on Aug 02, 2023 Mirion Technologies, Inc. announced that they will report Q2, 2023 results on Aug 02, 2023 Announcement • Jun 28
Mirion Technologies Introduces Genie™? 4.0 Spectroscopy Software, Now with Flexible Licensing Options Mirion Technologies announced a major update of the company's Genie spectroscopy software. With the release of Genie 4.0 software, Mirion builds upon nearly 40 years of leadership in spectroscopy solutions and services, delivering a range of new features that enhance efficiency and accuracy for both existing and new users, while introducing simplified software models and flexible purchasing options. Smart Design for All Longtime Genie software users will appreciate the seamless transition to Genie 4.0, as the update retains vital workflows and addresses key user requests, allowing them to maintain productivity and strengthen their expertise. Simultaneously, new users can quickly adapt to and harness the power of the Genie 4.0 release, ensuring evolved spectroscopy operations from the outset. Highlights of Genie 4.0 software include: User Experience Enhancements: Genie 4.0 features new Interactive Reports, enabling easier data visualization and detailed analysis, as well as customization per user requirements. Increased Accuracy and Reliable Results: New algorithms within Genie 4.0 improve uncertainty calculations for relationships in calibration standards and address a frequent user request for a new FWHM calibration curve, to further enhance accuracy. Improved Automation: New Python programming language-based scripting options enable custom and automated modulation of parameters, as well as extraction of specific parameters for analysis in a secondary system. Genie 4.0 software with Python compatibility also empowers users to perform custom calculations and update the analysis as needed, providing added flexibility and adaptability. Interested customers across the fields of Nuclear Power, Emergency Response, Environmental Labs, National Labs, Research, and Education are encouraged to view a free, introductory webinar, Latest in Gamma Spectroscopy: NewGenie 4.0 Software, on mirion.com. Continuous Support and Updates: In addition to a host of new features, the release of Genie 4.0 software introduces flexible new licensing models. Users now have the option to subscribe to the software over one-year or three-year terms with Priority Technical Support and software updates included, thereby lowering total cost of ownership and supporting Operational Expense (OpEx) budgeting. Users may also choose a non-expiring license via a one-time, upfront purchase. The new approach to licensing offers greater flexibility and ensures users can choose the option that best fits their needs. Genie 4.0 software will be available for download and licensing beginning mid-July. In the meantime, customers can explore the expanded features, service and support offering, flexible licensing options, and Genie 4.0 scripting resources. Announcement • May 13
Mirion Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $53.55 million. Mirion Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $53.55 million.
Security Name: Class A Common Stock
Security Type: Common Stock
Securities Offered: 7,000,000
Price\Range: $7.65 Announcement • May 06
Mirion Technologies, Inc. Reaffirms Revenue Guidance for the Fiscal Year Ending December 31, 2023 Mirion Technologies, Inc. reaffirmed revenue guidance for the fiscal year ending December 31, 2023. For the year, the company expected reported revenue growth of 6% - 9% and organic revenue growth of 4% - 7%. Reported Earnings • May 03
First quarter 2023 earnings released: US$0.22 loss per share (vs US$0.098 loss in 1Q 2022) First quarter 2023 results: US$0.22 loss per share (further deteriorated from US$0.098 loss in 1Q 2022). Revenue: US$182.1m (up 12% from 1Q 2022). Net loss: US$41.9m (loss widened 137% from 1Q 2022). Revenue is forecast to grow 4.7% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Electronic industry in Germany. Announcement • Feb 15
Mirion Technologies, Inc. Provides Revenue Guidance for the Fiscal Year Ending December 31, 2023 Mirion Technologies, Inc. provided revenue guidance for the fiscal year ending December 31, 2023. For the period, The company expects revenue growth of 6% to 9%, organic growth of 4% to 7%. Reported Earnings • Feb 15
Full year 2022 earnings released Full year 2022 results: US$1.38 loss per share. Revenue: US$717.8m (up 11% from FY 2021). Net loss: US$276.9m (loss widened 8.2% from FY 2021). Revenue is forecast to grow 4.6% p.a. on average during the next 2 years, compared to a 10.0% growth forecast for the Electronic industry in Germany. Announcement • Feb 01
Mirion Technologies, Inc. to Report Q4, 2022 Results on Feb 14, 2023 Mirion Technologies, Inc. announced that they will report Q4, 2022 results on Feb 14, 2023 Breakeven Date Change • Nov 18
No longer forecast to breakeven The 3 analysts covering Mirion Technologies no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$41.3m in 2023. New consensus forecast suggests the company will make a loss of US$19.8m in 2023. Reported Earnings • Nov 03
Third quarter 2022 earnings released: US$0.26 loss per share (vs US$7.01 loss in 3Q 2021) Third quarter 2022 results: US$0.26 loss per share. Revenue: US$160.9m (up 12% from 3Q 2021). Net loss: US$47.1m (flat on 3Q 2021). Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Electronic industry in Germany. Announcement • Nov 03
Mirion Technologies, Inc. Reaffirms Revenue Guidance for the Year 2022 Mirion Technologies, Inc. reaffirmed revenue guidance for the year 2022. The company have reaffirmed organic revenue growth guidance of 4% to 6%. Board Change • Oct 31
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 1 highly experienced director. Director Sheila Rege was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Oct 25
Mirion Technologies, Inc. to Report Q3, 2022 Results on Nov 01, 2022 Mirion Technologies, Inc. announced that they will report Q3, 2022 results After-Market on Nov 01, 2022 Announcement • Oct 04
Mirion Technologies Appoints Michael Rossi as President of Mirion Medical Mirion Technologies, Inc. announced the appointment of Michael Rossi as the President of Mirion Medical. Michael will report directly to Mirion’s CEO, Tom Logan, who had been acting as President of the business segment. Michael joins Mirion from Novartis, where he most recently served as the Head of Radioligand Imaging for the Advanced Accelerator Applications business. Prior to Novartis, Michael spent five years at Jubilant Pharma where he served in several different roles with increasing levels of responsibility. Michael also brings experience from GE Healthcare, Tyco Healthcare/Mallinckrodt and Syncor International to the Mirion team. Michael earned a Bachelor of Science in Pharmacy degree from the University of the Sciences – Philadelphia College of Pharmacy and carries the Authorized Nuclear Pharmacist Certification from Butler University. Michael has also served on several Boards of Directors and remains a Licensed Pharmacist in the state of Pennsylvania. Buying Opportunity • Oct 01
Now 20% undervalued Over the last 90 days, the stock is up 33%. The fair value is estimated to be €9.08, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 13% in a year. Earnings is forecast to grow by 75% in the next year. Announcement • Sep 20
Mirion Technologies, Inc. Announces Board Changes On September 13, 2022, Christopher Warren, a member of the board of directors (the “Board”) of Mirion Technologies, Inc. (the “Company”), notified the Company of his intent to resign from the Board, effective at the close of business on September 16, 2022. On September 16, 2022, after recommendation by the Nominating and Corporate Governance Committee of the Board, the Board appointed Ms. Sheila Rege, M.D., as a member of the Board, effective immediately, to fill the vacancy created by Mr. Warren’s resignation. Dr. Rege will stand for reelection as a member of the Board at the Company’s 2023 annual meeting of stockholders. Dr. Rege was also appointed to serve as a member of the Audit Committee and the Compensation Committee of the Board. Dr. Rege is a board-certified radiation oncologist and the Chief Executive Officer and Founder of Northwest Cancer Clinic. Dr. Rege joins the Mirion team with over 30 years of experience in the field of nuclear medicine and radiation oncology. From 2007 to 2019 Dr. Rege served on the board of directors of Physicians Insurance, serving as the Chair of the Nominating Committee and a member of the Compensation, Executive and CEO Succession Committee. Dr. Rege is the recipient of numerous awards and accolades including the American Medical Association Women Physician Section Inspiration Award in 2021, the Private Company Boardroom 2022 “Directors to Watch,” The American College of Radiation Oncology 2022 Sucha Asbell Mentorship Award, and has been recognized as a “Top Oncologist” by Consumer Research Council of America in 2012. Dr. Rege received her B.A. from the University of California, Berkeley, and her M.D. from the University of California, Los Angeles. Buying Opportunity • Sep 03
Now 23% undervalued after recent price drop Over the last 90 days, the stock is down 3.4%. The fair value is estimated to be €9.17, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 13% in a year. Earnings is forecast to grow by 96% in the next year. Breakeven Date Change • Sep 01
Forecast breakeven date pushed back to 2023 The 3 analysts covering Mirion Technologies previously expected the company to break even in 2022. New consensus forecast suggests losses will reduce by 77% to 2022. The company is expected to make a profit of US$41.3m in 2023. Average annual earnings growth of 154% is required to achieve expected profit on schedule. Announcement • Aug 10
Mirion Technologies, Inc. (NYSE:MIR) acquired ARINC Incorporated from Collins Aerospace. Mirion Technologies, Inc. (NYSE:MIR) acquired ARINC Incorporated from Collins Aerospace on August 9, 2022.
Mirion Technologies, Inc. (NYSE:MIR) completed the acquisition of ARINC Incorporated from Collins Aerospace on August 9, 2022. Reported Earnings • Jul 30
Second quarter 2022 earnings released: US$0.32 loss per share (vs US$8.14 loss in 2Q 2021) Second quarter 2022 results: US$0.32 loss per share. Revenue: US$175.8m (down 2.3% from 2Q 2021). Net loss: US$58.6m (loss widened 8.7% from 2Q 2021). Over the next year, revenue is forecast to grow 13%, compared to a 20% growth forecast for the industry in Germany. Announcement • Jul 16
Mirion Technologies, Inc. to Report Q2, 2022 Results on Jul 29, 2022 Mirion Technologies, Inc. announced that they will report Q2, 2022 results on Jul 29, 2022 Announcement • May 21
Mirion Technologies, Inc. Appoints Christopher Moore as Principal Accounting Officer On May 18, 2022, Mirion Technologies, Inc. appointed Christopher Moore as Principal Accounting Officer, effective immediately. Mr. Moore joined the Corporation in April 2022 and, in his new role, will lead the global accounting organization and be responsible for advancing the Corporation's accounting and internal financial controls. Mr. Moore will report directly to the Corporation's CFO, Brian Schopfer. Reported Earnings • May 08
First quarter 2022 earnings released: US$0.098 loss per share (vs US$6.18 loss in 1Q 2021) First quarter 2022 results: US$0.098 loss per share (up from US$6.18 loss in 1Q 2021). Revenue: US$163.2m (down 1.8% from 1Q 2021). Net loss: US$17.7m (loss narrowed 56% from 1Q 2021). Over the next year, revenue is forecast to grow 12%, compared to a 28% growth forecast for the industry in Germany. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 1 highly experienced director. Founder, CEO & Director Tom Logan was the last director to join the board, commencing their role in 2005. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Announcement • Apr 12
Mirion Technologies, Inc. Introduces New SaaS Option for its SunCHECK™ Quality Management Platform Mirion Technologies, Inc. announced the release of an enhanced Cloud-hosted, SaaS option for its SunCHECK™ Quality Management Platform. Through a centralized database and single interface, the SunCHECK Platform streamlines and standardizes workflows for Radiation Therapy Quality Assurance (QA) – to reduce risk and improve Patient Safety in cancer care. The SaaS model offers scalability, security, and operational efficiencies for health systems looking to integrate and automate QA, with a comprehensive, proven solution. Local management of software and servers can be burdensome, requiring capital for server hardware. Cloud-hosted, SaaS implementation of the SunCHECK Platform reduces the time and resources required for upfront deployment and ongoing support. SunCHECK users and their IT departments can be assured of reliability, redundancy, and security, with Amazon Web Services as the Cloud provider for the SunCHECK SaaS option. The SunCHECK SaaS solution can be customized to meet any clinic’s radiation oncology quality management needs and is accessed through a secure Internet connection. At this time, the SunCHECK SaaS Solution is available for new SunCHECK Platform customers in approved markets only. The SunCHECK software will be featured, and available for demonstration, in the Sun Nuclear booth during ESTRO 2022, May 6-10, in Copenhagen, Denmark. ESTRO 2022 is the annual meeting of the European Society for Radiotherapy and Oncology, with a membership base of 7,600 Radiation Oncology professionals globally. Announcement • Mar 10
Mirion Technologies, Inc. (NYSE:MIR) acquired Safeline Monitors Systems LLC for $1.5 million. Mirion Technologies, Inc. (NYSE:MIR) acquired Safeline Monitors Systems LLC for $1.5 million on December 1, 2021. The total consideration of $1.5 million includes $0.5 million contingent consideration, based on actual revenues from existing customers for 6 months subsequent to the transaction date.
Mirion Technologies, Inc. (NYSE:MIR) completed the acquisition of Safeline Monitors Systems LLC on December 1, 2021. Reported Earnings • Mar 06
Full year 2021 earnings: Revenues in line with analyst expectations Full year 2021 results: Revenue: US$644.2m (up 13% from FY 2020). Net loss: US$255.8m (loss widened 65% from FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 13%, compared to a 23% growth forecast for the industry in Germany. 
